Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation

Asian Journal of Andrology

Volumn 16, Issue 4, 2014, Pages 541-544

  Lipianskaya, Julia ^a   Cohen, Alexa ^a   Chen, Clark J ^a   Hsia, Elaine ^a   Squires, Jill ^a   Li, Zhen ^a   Zhang, Yaqun ^a   Li, Wei ^a   Chen, Xufeng ^a   Xu, Hua ^a   Huang, Jiaoti ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

neuroendocrine; prostate cancer; small cell carcinoma; therapy

Indexed keywords

ANDROGEN; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; PROTEIN P53;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL HETEROGENEITY; GENE INACTIVATION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SMALL CELL NEUROENDOCRINE CARCINOMA;

EID: 84904744278     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.123669     Document Type: Review

References (30)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61.
2. Mitsiades N. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 2013; 73: 4599-605.
3. Hagood PG, Johnson FE, Bedrossian CW, Silverberg AB. Small cell carcinoma of the prostate. Cancer 1991; 67: 1046-50.
4. Ferraldeschi R, de Bono J. Agents that target androgen synthesis in castration-resistant prostate cancer. Cancer J 2013; 19: 34-42.
5. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013; 19: 43-9.
6. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2013 Jun 10. [Epub ahead of print].
7. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-9.
8. Cunha GR, Ricke WA. A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation 2011; 82: 168-72.
9. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002; 70: 473-85.
10. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1: 148-62.
11. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-47.
12. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147-55.
13. Merrimen JL, Evans AJ, Srigley JR. Preneoplasia in the prostate gland with emphasis on high grade prostatic intraepithelial neoplasia. Pathology 2013; 45: 251-63.
14. Huang J, Yao JL, di Sant'agnese PA, Yang Q, Bourne PA, et al. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006; 66: 1399-406.
15. Yao JL, Madeb R, Bourne P, Lei J, Yang X, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006; 30: 705-12.
16. Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71.
17. Chen H, Sun Y, Wu C, Magyar CE, Li X, et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer 2012; 19: 321-31.
18. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009; 40: 252-8.
19. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000; 13: 238-42.
20. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006; 30: 684-93.
21. Nadig SN, Deibler AR, El Salamony TM, Hull GW, Bissada NK. Small cell carcinoma of the prostate: an underrecognized entity. Can J Urol 2001; 8: 1207-10.
22. Nguyen-Ho P, Nguyen GK, Villanueva RR. Small cell anaplastic carcinoma of the prostate: report of a case with positive urine cytology. Diagn Cytopathol. 1994; 10: 159-61.
23. Okada H, Gotoh A, Ogawa T, Arakawa S, Ohbayashi C, et al. Two cases of small cell carcinoma of the prostate. Scand J Urol Nephrol 1996; 30: 503-8.
24. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147: 804-7.
25. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166: 1807-15.
26. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487-95.
27. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227: 286-97.
28. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34: 22-9.
29. Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-9.
30. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621-30.